Harrow, Inc. Proceeds from Sale of Productive Assets
Harrow, Inc. (HROW) reported Proceeds from Sale of Productive Assets of $6.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2023-03-23
- Harrow, Inc. proceeds from sale of productive assets for the quarter ending 2019-12-31 was $0.00.
- Harrow, Inc. proceeds from sale of productive assets for the quarter ending 2019-03-31 was $4.00K.
- Harrow, Inc. proceeds from sale of productive assets for fiscal 2022 was $6.00M.
- Harrow, Inc. proceeds from sale of productive assets for fiscal 2020 was $13.00K, a 225.00% increase from fiscal 2019.
- Harrow, Inc. proceeds from sale of productive assets for fiscal 2019 was $4.00K.
- Harrow, Inc. proceeds from sale of productive assets for fiscal 2017 was $113.00K.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|
| 2022-12-31 | $6.00M 10-K · filed 2023-03-23 | ||
| 2020-12-31 | $13.00K 10-K · filed 2022-03-10 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $4.00K 10-K · filed 2021-03-08 | |
| 2019-09-30 | $4.00K 10-Q · filed 2020-11-09 | ||
| 2019-03-31 | $4.00K 10-Q · filed 2020-05-11 | ||
| 2017-12-31 | $113.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |